Table 1 Clinical characteristics of MM patients in POD24 group and non-POD24 group.
Clinical character | POD24 (n = 158) | Non-POD24 (n = 315) | P | |
|---|---|---|---|---|
Age | 62.7(40–90) | 61.4(24–85) | 0.197 | |
Gender | Male | 92(58.2%) | 171(54.3%) | 0.399 |
Female | 66(41.8%) | 144(45.7%) | ||
Hemoglobin (g/L) | 85.1(37–169) | 91(43–163) | 0.017 | |
Blood calcium (mmol/L) | 2.37(1.38–5.35) | 2.27(1.61–4.05) | 0.030 | |
Creatinine(umol/L) | 164.1(38-1197.8) | 166.7(30-1286.7) | 0.904 | |
β2 microglobulin (ug/L) | 8.5(0.26–39.02) | 9.32(0.1–343) | 0.667 | |
Lactate dehydrogenase(U/L) | 195.1(50-1102) | 194.4(25.4–4322) | 0.987 | |
ISS staging | I | 23(14.6%) | 47(14.9%) | 0.331 |
II | 51(32.3%) | 122(38.7%) | ||
III | 84(53.2%) | 146(46.3%) | ||
Treatment | Contains bortezomib | 118(74.7%) | 227(72.1%) | 0.545 |
Without bortezomib | 40(25.3%) | 88(27.9%) | ||
R-ISS staging | I | 18(11.4%) | 38(12.1%) | 0.910 |
II | 110(69.6%) | 222(70.5%) | ||
III | 30(19.0%) | 55(17.5%) | ||
Transplant state | Transplant | 24(15.2%) | 72(22.9%) | 0.051 |
Non-transplant | 134(84.8%) | 243(77.1%) | ||
Chromosomal | Normal | 96(60.8%) | 227(72.1%) | 0.013 |
Abnormal | 62(39.2%) | 88(27.9%) | ||
